Melanoma-associated antigen C2 (42-50)

Melanoma-associated antigen C2 (42-50) is a synthetic peptide fragment derived from the larger melanoma-associated antigen C2 protein, specifically encompassing amino acid residues 42 to 50. As a defined epitope, this peptide holds significant relevance in tumor immunology and cancer research, particularly for studies involving antigen processing and presentation. Its sequence is recognized for its role in immune recognition, making it a valuable tool for investigating T cell responses to melanoma antigens. The defined nature of this peptide supports its use in a variety of biochemical and immunological applications, enabling precise mechanistic studies and facilitating the development of novel research methodologies related to tumor-associated antigens.

Epitope mapping: Researchers utilize this peptide fragment to delineate the precise regions of melanoma-associated antigens that are recognized by cytotoxic T lymphocytes (CTLs). By incorporating the 42-50 sequence into in vitro assays, scientists can systematically identify T cell epitopes, thereby enhancing understanding of antigenic determinants involved in tumor immunity. This approach enables the fine mapping of immune-reactive sites, which is essential for both basic research and for informing the design of immunotherapeutic strategies targeting melanoma.

Immunogenicity assessment: The 42-50 peptide is frequently employed in assays that evaluate the functional capacity of immune cells to recognize melanoma antigens. For example, it can be used to stimulate peripheral blood mononuclear cells (PBMCs) or isolated T cell populations in vitro, allowing researchers to measure cytokine production, proliferation, or cytolytic activity in response to antigen exposure. Such studies provide critical insights into the immunogenic potential of tumor-associated peptides and support the identification of key immune effector mechanisms.

Peptide-MHC binding studies: The defined sequence of the melanoma-associated antigen C2 (42-50) peptide makes it an ideal candidate for investigating major histocompatibility complex (MHC) binding specificity. By analyzing the interaction between this peptide and various MHC class I molecules, researchers can elucidate the structural and biochemical requirements for effective antigen presentation. These studies are fundamental for understanding how tumor peptides are displayed on the cell surface and subsequently recognized by T cells, which has direct implications for the development of targeted immunotherapies.

Synthetic peptide controls: In experimental immunology and peptide biochemistry, this fragment serves as a reliable positive control for method validation and assay calibration. Its well-characterized sequence and immunological relevance make it suitable for benchmarking the performance of peptide synthesis, purification protocols, and analytical techniques such as mass spectrometry or HPLC. By providing a consistent standard, the peptide supports reproducibility and quality assurance across a range of experimental platforms.

Vaccine research models: The use of this peptide in preclinical research models allows for the evaluation of antigen-specific immune responses in the context of melanoma. By incorporating the 42-50 sequence into peptide-based vaccine formulations or delivery systems, investigators can study the induction of targeted T cell responses and assess the efficacy of candidate immunogens in stimulating anti-tumor immunity. These applications are instrumental in advancing the development of next-generation immunotherapeutic strategies and in refining approaches for cancer vaccine design.

1. TMEM16F and dynamins control expansive plasma membrane reservoirs

2. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance

3. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry

4. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

5. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die